Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ITOC 2020 | SB2115 plus nivo for solid tumors

Filip Janku • 28 Sep 2020
ITOC 2020
General Antibodies Nivolumab SB 11285

Filip Janku, MD, PhD, Anderson Cancer Center, The University of Texas, Houston, TX, outlines the use of SB 11285, a novel STING agonist, and nivolumab, a human immunoglobulin G4 monoclonal antibody for the treatment of solid tumors. This interview took place during the 7th Immunotherapy of Cancer Conference (ITOC) 2020.

More from Filip Janku

5:12
First-in-human trial of an EGFR/TGFβ fusion protein for advanced solid tumors
Filip Janku • 19 May 2021
7:15
Rebastinib plus paclitaxel shows encouraging anti-tumor activity in endometrial cancer
Filip Janku • 19 May 2021
2:29
Developmental therapeutics updates to look at for at ASCO 2021
Filip Janku • 19 May 2021
8:12
First-in-human trial of intratumoral injection of SYNB1891
Filip Janku • 10 Apr 2021

Related Videos

0:29
Innovative ctDNA-based liquid biopsy techniques for cancer diagnosis
Alain Thierry • 9 Apr 2024
0:50
Employing fragmentomics as a novel strategy to characterize and detect cancers
Alain Thierry • 9 Apr 2024
1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
3:10
PALOMA: subcutaneous amivantamab in advanced solid tumors
Natasha Leighl • 17 Apr 2024
The content of VJOncology is intended for healthcare professionals